MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Healthcare Partners, a leading healthcare-focused investment firm founded in 1991, announced the promotion of three investment professionals to the life sciences team: Dan Estes, Ph. .D. to the Partner; Rémy Durand, Ph.D. to Vice President; and Jamie Brush, MD at Senior Associate.
Dan Estes joined the Frazier Life Sciences team in 2011 and serves on the boards of Semnur Pharmaceuticals and Outpost Medicine. He also played a key role in Frazier’s investments in Acerta Pharma (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Cidara Therapeutics (NASDAQ: CDTX), Precision Dermatology (acquired by Valeant), Millendo Therapeutics and Entasis Therapeutics. , among others. .
Remy Durand joined Frazier in 2015 and has been involved in all life science transactions since then. He is an observer on the boards of Alpine Immune Sciences, Aptinyx Inc., Iterum Therapeutics and Zavante Therapeutics.
Jamie Brush joined the Frazier Life Sciences team in 2016. Prior to joining Frazier, he was a management consultant at Boston Consulting Group. He received his MD from the University of Southern California.
Managing General Partner Patrick Heron said, “We are very pleased to see the continued progress of our investment team. Dan, Remy and Jamie have each contributed greatly to our record year of life sciences achievement following the launch of our first Life Sciences fund in early 2016.”
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading US-based healthcare-focused investment firm that provides private growth capital to healthcare companies. The firm has more than $2.9 billion in committed capital under management and has made investments in more than 170 companies, ranging from early-stage venture capital investments to growth buyouts of profitable lower-middle-market companies. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging their deep domain expertise and extensive network of healthcare executives, advisors and thought leaders . The Frazier Life Sciences Fund and the Frazier Healthcare Growth Buyout Fund are the two vehicles used to invest in early-stage life science companies and profitable lower-middle-market growth buyout companies, respectively. While these strategies target companies in distinctly different market segments and stages of development, both investment teams leverage the company’s rich 26-year history to identify and partner with exceptional management teams. in order to develop leading companies. Frazier has offices in Seattle, Washington, and Menlo Park, California, and invests extensively in the United States, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.